The Center for Urologic Oncology at the Glickman Urological & Kidney Institute is the largest center within the Department of Urology.
The membership of the Center boasts 10 fellowship-trained, internationally-recognized leaders in bladder, kidney, prostate, and testis cancer who are supported by an integrated team of experienced mid-level practitioners (including nurse practitioners and physicians assistants).
The surgeons within the Center perform robotic and open procedures to treat these cancers, often in a multi-disciplinary team approach with the integration of expertise by medical oncology and/or radiation oncology.
The Center has a rich history of technical innovations which have transformed the management of these cancers including open partial nephrectomy, laparoscopic/robotic partial nephrectomy, radical nephrectomy and venous thrombectomy for advanced kidney cancer, open/robotic radical prostatectomy and robotic radical cystectomy.
The Center has also been at the forefront of pioneering less-invasive treatment alternatives (where appropriate) for urologic cancers such as active surveillance, cryotherapy, and focal therapy for localized prostate cancer and percutaneous ablative procedures for small renal masses.
Annually, surgeons within the Center perform approximately 500 partial/radical nephrectomy procedures for kidney cancer, 450 prostatectomy procedures for prostate cancer, 140 cystectomy procedures for bladder cancer, and 40 retroperitoneal lymph node dissections for testis cancer.
The Center has unique expertise in managing rare urologic cancers (such as cancers of the penis, urethra, adrenal gland, and genitourinary sarcomas) and salvage procedures for recurrent cancers of the bladder and prostate that have failed initial therapy with radiation or other treatments.
The clinical activities of the Center are supported by world-class clinical experts in pathology, radiology, and anesthesia.
The Center also supports research programs in patient-centered outcomes research, prostate cancer/androgen receptor biology, and kidney cancer.
Prostate Cancer Nutrition Program
What you eat can impact your prostate cancer and certain foods may influence cancer survival.
About one in seven men will be diagnosed with prostate cancer at some point in their lives, according to the American Cancer Society. However, the simple act of eating the right foods can improve your chances of becoming a prostate cancer survivor.
Some foods fuel disease
Experts — backed by research — believe some foods can impact prostate cancer growth. Since sugary foods, red meat and dairy products are believed to provide fuel to cancer cells, prostate cancer patients are encouraged to modify their diet by:
- Limiting red meat and eating it no more than two or three times per month.
- Eating lots of fruits and vegetables.
- Significantly limiting dairy and sugary foods.
Vitamins and supplements also play a role in prostate cancer
Including supplements and vitamins in your diet can also be beneficial.
- Increase consumption of omega-3 fatty acids. Foods like salmon, chia seeds, sardines and flaxseeds are rich in omega-3s.
- Decrease intake of omega-6 fatty acids. Foods like hamburgers, hot dogs, french fries and chicken wings are high in omega-6s.
- Vitamin D also has shown to play a role in prostate cancer.
Cleveland Clinic Prostate Cancer Nutrition Program
David Levy, MD, a urologist in the Glickman Urological & Kidney Institute, has a special interest in the role foods and supplements play in prostate cancer and leads the Prostate Cancer Nutrition Program. If you have or have had prostate cancer, or have a family history of prostate cancer, the Prostate Cancer Nutrition Program can help you understand whether diet and supplement changes might benefit you. For more information or to schedule an appointment, call 216.692.8900.
What We Treat
- Bladder cancer
- Kidney cancer
- Prostate cancer
- Testis cancer
- Adrenal cancer
- Penile cancer
- Urethral cancer
- Genitourinary sarcoma
Treatments and Procedures
- Bladder Tumor Biopsy and Resection
- Focal therapy for localized prostate cancer
- High Intensity Focused Ultrasound (Hifu)
- Inguinal Lymph Node Dissection
- Open Partial Nephrectomy
- Robotic and Open Radical Cystectomy (including continent urinary diversion or 'neobladder')
- Robotic Partial Nephrectomy
- Robotic and Open Radical nephrectomy (including venous thrombectomy)
- Robotic and Open Radical Nephroureterectomy
- Percutaneous and laparoscopic renal mass ablation
- Robotic and Open Radical Prostatectomy
- Salvage robotic and open radical prostatectomy
- Prostate Cryoablation
- Salvage prostate cryoablation
- Robotic and open retroperitoneal lymph node dissection
- Robotic and Open Adrenalectomy
- Radical and Partial Penectomy/Urethrectomy and Inguinal Lymph Node Dissection
- Radical Nephrectomy
For more information, view treatment guides from the Glickman Urological and Kidney Institute.
Research & Innovations
Kidney Tumor Location Measurement Using the C Index Method
A downloadable Microsoft® Excel spreadsheet is available to enable clinicians to rapidly determine 'C index' values from the 'y', 'x' and 'd' values of planar CT images.